Wang, Yuwei
Dackus, Gwen M. H. E.
Rosenberg, Efraim H.
Cornelissen, Sten
de Boo, Leonora W.
Broeks, Annegien
Brugman, Wim
Chan, Terry W. S.
van Diest, Paul J.
Hauptmann, Michael
ter Hoeve, Natalie D.
Isaeva, Olga I.
de Jong, Vincent M. T.
Jóźwiak, Katarzyna
Kluin, Roelof J. C.
Kok, Marleen
Koop, Esther
Nederlof, Petra M.
Opdam, Mark
Schouten, Philip C.
Siesling, Sabine
van Steenis, Charlaine
Voogd, Adri C.
Vreuls, Willem
Salgado, Roberto F.
Linn, Sabine C.
Schmidt, Marjanka K. http://orcid.org/0000-0002-2228-429X
Funding for this research was provided by:
KWF Kankerbestrijding (No. 11655/2018-1)
ZonMw (Project number 836021019)
Stichting A Sister's Hope
Breast Cancer Research Foundation (grant No. 17-194)
Ministerie van Volksgezondheid, Welzijn en Sport
Article History
Received: 21 July 2023
Accepted: 15 December 2023
First Online: 9 January 2024
Declarations
:
: The study was approved by the Institutional Review Board of the Netherlands Cancer Institute (IRB code: CFMPB554). All retrospective medical data/biospecimen studies in the Netherlands are executed pursuant to Dutch legislation, international standards, and a self-regulatory Code of Conduct (ExternalRef removed). Prior to 25 May 2018, national legislation on data protection applied, as well as the International Guideline on Good Clinical Practice. From 25 May 2018, hospitals in the Netherlands also have to adhere to the General Data Protection Regulation. Within this framework, patients are informed and have the opportunity to object or actively consent to the (continued) use of their personal data and biospecimens in research. Hence, the procedures comply both with (inter-) national legislative and ethical standards.
: Not applicable.
: SL has been an advisory board member for AstraZeneca, Cergentis, IBM, Novartis, Pfizer, Roche, and Sanofi and has received unrestricted institutional research support or unrestricted educational funding from Agendia, Amgen, AstraZeneca, Bayer, Daiichi Sankyo, Eurocept Pharmaceuticals, Genentech, Immunomedics, Merck, Roche, Sanofi, and TESARO. PS and SL have a pending patent application for a <i>BRCA</i>-like ovarian cancer classifier. PD has a pending patent application for DDX3 as a biomarker for cancer and its related methods. MK has been an advisory board member for Bristol Myers Squibb/Medarex, Roche, MSD, and AZ/Daiichi and has received research funding from Bristol Myers Squibb, Roche, and AstraZeneca/MedImmune. RS has received non-financial support from Merck and Bristol Myers Squibb (BMS); research support from Merck, Puma Biotechnology, and Roche; and personal fees from Roche, BMS, and Exact Sciences for advisory boards. The other authors declare that they have no competing interests.